Medtronic on Jan. 8 acquired Stimgenics, developer of the Differential Target Multiplexed spinal cord stimulation therapy.
Four things to know:
1. The DTM spinal cord stimulation therapy is a programming option used to treat patients with chronic pain and is administered through the Medtronic Intellis system.
2. Medtronic will present three month results from a randomized control trial studying DTM versus traditional SCS at the North American Neuromodulation Society 23rd Annual Meeting in Las Vegas from Jan. 23 to 26.
3. The transaction is expected to be neutral to Medtronic's fiscal year 2020 earnings per share and meet its long-term financial goals for acquisitions.
4. Additional terms of the deal were not disclosed.